An observational study in Drug-Related Side Effects and Adverse Reactions and Treatment Adherence and Compliance, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · France.
Among the 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2024, is one of 21 observational ones, and was the 30th registered.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
Browse Drug-Related Side Effects and Adverse Reactions studies →7 of the 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in France, United States, Australia and 7 more countries
Ages 18+
University Hospital, Caen · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 65+
Groupe Hospitalier Pitie-Salpetriere · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 60 is below the median of 414 across 162 observational studies indexed under Drug-Related Side Effects and Adverse Reactions.
Median enrollment 170 across the 14 interventional studies, 1,100 across the 21 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 35 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 4 studies filed under Drug-Related Side Effects and Adverse Reactions — fewer than ten, so there is no comparison to draw.
1 of the studies in Drug-Related Side Effects and Adverse Reactions with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07169851Eli Lilly and CompanyA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.
patients having a BJI treated by at least one oral antibiotic after a surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
Other: Tolerance and adherence to oral antibiotics in patients managed for BJI
Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire). Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3. Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.
Percentage of doses taken at 6 weeks
Ratio of the number of doses taken over the theoretical number of doses to be taken over the period
Time frame: At 6 weeks after surgery
Percentage of doses taken at 3 months
Ratio of the number of doses taken over the theoretical number of doses to be taken over the period
Time frame: at 3 months after surgery
Started Jun 2024 (actual). Primary completion is estimated for Sep 2028, 51 months after the start.
Of 65 non-industry observational studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24. This study's planned 51 months is below that.
Counting every sponsor, half of 69 studies reached it within 45 months; a quarter within 24 and three quarters within 97.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions →